Anlon Healthcare Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare Limited has filed an annual disclosure under SEBI Regulation 31(4) on behalf of its Promoter and Promoter Group for the financial year 2025-2026. The disclosure confirms that none of the 19 individuals and entities in the promoter group — including Managing Director Punitkumar Rasadia and entities such as Anlon Chemical Research Organization, Anlon Lifescience Private Limited, and Advintel Mediccare Private Limited — have created any encumbrance (such as pledge or lien) on their shares, either directly or indirectly, during the entire financial year. This is a standard regulatory filing required annually from promoters of listed companies.
A clean encumbrance-free declaration is a positive signal for minority shareholders as it indicates promoters have not leveraged their shareholding, reducing risk of sudden dilution or forced selling. The stock is not under immediate pledge-related pressure.